China to inject billions into grassroots health services
This article was originally published in Scrip
A new initiative under China's health care reform program, which over the past few years has helped propel the country's pharmaceutical sector to astonishing 20%-plus growth rates, was launched by China's influential policy czar, the National Development and Reform Commission (NDRC), on the eighth day of the eighth month (8 August), a date deemed lucky in China.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.